Noxilizer is pioneering the development of a unique and superior sterilization technology that will revolutionize two major sterilization markets — hospitals and biotherapeutics. In hospitals, Noxilizer is developing a system especially for the sensitive high-tech equipment increasingly used in minimally invasive surgical procedures. In the biotherapeutics market, the development of next-generation therapies for cardiovascular disease, cancer, and diabetes is constrained by current sterilization technologies which destroy chemical, biologic, and mechanical properties of many products. Noxilizer’s room-temperature system has shown great potential to be an enabling technology for a wide range of products, including antibodies, proteins, drug-device combination products, nanoparticles, and implants. Noxilizer is committed to providing innovative solutions for healthcare professionals and their patients.

RECENT NEWS:
Mar 2009 | Noxilizer's breakthrough sterilization technology is featured in the March issue of Medical Device & Diagnostic Industry with the headline "Will a Sterilization Rookie become the Next MVP?" MD&DI is a monthly peer-reviewed journal (circulation 45,000) written exclusively for manufacturers of medical devices and in vitro diagnostic products. You may read the article at http://www.devicelink.com/mddi/archive/09/03/004.html.